250 related articles for article (PubMed ID: 22806891)
21. Cytoplasmic calcium increase via fusion with inactivated Sendai virus induces apoptosis in human multiple myeloma cells by downregulation of c-Myc oncogene.
Jiang Y; Saga K; Miyamoto Y; Kaneda Y
Oncotarget; 2016 Jun; 7(24):36034-36048. PubMed ID: 27145280
[TBL] [Abstract][Full Text] [Related]
22. [Regulation of c-myc expression by Blimp-1 during the differentiation of myeloma cells].
Zhou X; Zhou F; Jiang H; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2007 May; 28(5):318-22. PubMed ID: 17877160
[TBL] [Abstract][Full Text] [Related]
23. N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma.
Edwards SK; Moore CR; Liu Y; Grewal S; Covey LR; Xie P
BMC Cancer; 2013 Oct; 13():481. PubMed ID: 24131623
[TBL] [Abstract][Full Text] [Related]
24. HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications.
Harada T; Ohguchi H; Grondin Y; Kikuchi S; Sagawa M; Tai YT; Mazitschek R; Hideshima T; Anderson KC
Leukemia; 2017 Dec; 31(12):2670-2677. PubMed ID: 28490812
[TBL] [Abstract][Full Text] [Related]
25. c-Myc, RMRP, and miR-34a-5p form a positive-feedback loop to regulate cell proliferation and apoptosis in multiple myeloma.
Xiao X; Gu Y; Wang G; Chen S
Int J Biol Macromol; 2019 Feb; 122():526-537. PubMed ID: 30389523
[TBL] [Abstract][Full Text] [Related]
26. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma.
Podar K; Tonon G; Sattler M; Tai YT; Legouill S; Yasui H; Ishitsuka K; Kumar S; Kumar R; Pandite LN; Hideshima T; Chauhan D; Anderson KC
Proc Natl Acad Sci U S A; 2006 Dec; 103(51):19478-83. PubMed ID: 17164332
[TBL] [Abstract][Full Text] [Related]
27. Oncogene addiction to c-MYC in myeloma cells.
Holien T; Sundan A
Oncotarget; 2012 Aug; 3(8):739-40. PubMed ID: 22964579
[No Abstract] [Full Text] [Related]
28. The Selective SIRT3 Inhibitor 3-TYP Represses Primary Myeloma Growth by Reducing c-Myc Stability.
Zeng Y; Zhang Y; Cui Z; Mao J; Xu J; Yao R
Chem Res Toxicol; 2024 Jun; 37(6):1062-1069. PubMed ID: 38815162
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells.
Wang J; Ma X; Jones HM; Chan LL; Song F; Zhang W; Bae-Jump VL; Zhou C
J Transl Med; 2014 Aug; 12():226. PubMed ID: 25143136
[TBL] [Abstract][Full Text] [Related]
30. FGF signaling inhibits the proliferation of human myeloma cells and reduces c-myc expression.
Firme L; Bush AB
BMC Cell Biol; 2003 Dec; 4():17. PubMed ID: 14656381
[TBL] [Abstract][Full Text] [Related]
31. MUC1-C drives MYC in multiple myeloma.
Tagde A; Rajabi H; Bouillez A; Alam M; Gali R; Bailey S; Tai YT; Hideshima T; Anderson K; Avigan D; Kufe D
Blood; 2016 May; 127(21):2587-97. PubMed ID: 26907633
[TBL] [Abstract][Full Text] [Related]
32. Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids.
Wang H; Teriete P; Hu A; Raveendra-Panickar D; Pendelton K; Lazo JS; Eiseman J; Holien T; Misund K; Oliynyk G; Arsenian-Henriksson M; Cosford ND; Sundan A; Prochownik EV
Oncotarget; 2015 Oct; 6(32):32380-95. PubMed ID: 26474287
[TBL] [Abstract][Full Text] [Related]
33. Dissecting the impact of bromodomain inhibitors on the Interferon Regulatory Factor 4-MYC oncogenic axis in multiple myeloma.
Agnarelli A; Mitchell S; Caalim G; Wood CD; Milton-Harris L; Chevassut T; West MJ; Mancini EJ
Hematol Oncol; 2022 Aug; 40(3):417-429. PubMed ID: 35544413
[TBL] [Abstract][Full Text] [Related]
34. The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival.
Bommert KS; Effenberger M; Leich E; Küspert M; Murphy D; Langer C; Moll R; Janz S; Mottok A; Weissbach S; Rosenwald A; Bargou R; Bommert K
Leukemia; 2013 Feb; 27(2):441-50. PubMed ID: 22772059
[TBL] [Abstract][Full Text] [Related]
35. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
[TBL] [Abstract][Full Text] [Related]
36. Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc/Max heterodimerization and disturbing its stability.
Yao R; Zhang M; Zhou J; Liu L; Zhang Y; Gao J; Xu K
Cell Commun Signal; 2022 May; 20(1):73. PubMed ID: 35619182
[TBL] [Abstract][Full Text] [Related]
37. DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling.
Ishiguro K; Kitajima H; Niinuma T; Ishida T; Maruyama R; Ikeda H; Hayashi T; Sasaki H; Wakasugi H; Nishiyama K; Shindo T; Yamamoto E; Kai M; Sasaki Y; Tokino T; Nakase H; Suzuki H
Haematologica; 2019 Jan; 104(1):155-165. PubMed ID: 30171029
[TBL] [Abstract][Full Text] [Related]
38. Telomerase inhibitor MST-312 induces apoptosis of multiple myeloma cells and down-regulation of anti-apoptotic, proliferative and inflammatory genes.
Ameri Z; Ghiasi S; Farsinejad A; Hassanshahi G; Ehsan M; Fatemi A
Life Sci; 2019 Jul; 228():66-71. PubMed ID: 31029779
[TBL] [Abstract][Full Text] [Related]
39. The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma.
Crawford LJ; Campbell DC; Morgan JJ; Lawson MA; Down JM; Chauhan D; McAvera RM; Morris TC; Hamilton C; Krishnan A; Rajalingam K; Chantry AD; Irvine AE
Oncogene; 2020 Jul; 39(27):5001-5014. PubMed ID: 32523091
[TBL] [Abstract][Full Text] [Related]
40. TAZ functions as a tumor suppressor in multiple myeloma by downregulating MYC.
Grieve S; Wajnberg G; Lees M; Chacko S; Weir J; Crapoulet N; Reiman T
Blood Adv; 2019 Nov; 3(22):3613-3625. PubMed ID: 31743393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
